Tagged with R

Russia This ranking for 2013 of the top 20 pharmaceutical products sold in the Russian hospital market during the year, organized by sales value, demoninates each drug according to its international nonproprietary name (INN), as denominated by the World Health Organization (WHO). Source: Pharmon / Aston Consulting

Russia As the rankings for the hospital market by sales value show, in Russia, it is multinational companies that dominate, with no local companies featuring on the top 20 ranking Source: Pharmon / Aston Consulting

Argentina Central nervous system, metabolic and cardiovascular products were the best performing therapeutic areas in Argentina in 2012, according to the graph below, which looks at market sales broken down by therapeutic area.

chronic pain Bene Farmacêutica was established in 2009 to expand the supply and presence of Bene-Arzneimittel in Portugal, having already sold products in the country for several decades. The affiliate’s managing director, Frank Tischler, outlines Bene Farmacêutica’s entrance into Portugal and discusses the importance of adding value to brands in an environment…

law “The advantage of working in a law firm such as SRS Advogados is that it favors specialization in specific legal areas, such as life sciences, in order to meet the client’s needs. The regulatory aspects require study and preparation and are the main aspects of the legal advice of the…

Infarmed Eurico Castro Alves, president of Portugal’s regulatory agency Infarmed, talks about the biggest challenges facing the regulation of health products in the country today, and introduces new initiatives aimed at positioning Infarmed as a regulator of reference worldwide.   You have been president of Infarmed since 2012. What have been some…

Pfizer “Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we reverse the trends observed concerning our levels of local investment in R&D, namely through the attraction of more clinical trials…

biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success.   Bluepharma…

biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success.   Bluepharma…

biotech Portuguese pharmaceutical group Bluepharma consists of ten companies that represent different parts of the medicine value chain. The success of Bluepharma during Portugal’s crisis was due to a strong focus on overseas exports and diversification of risk. Paulo Barradas and Sérgio Simões explain how they created that success.   Bluepharma…

R&D Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui Santos explains this process and how he plans to tackle the tough Portuguese marketplace.   Almirall has been in Portugal…

market access José Aranda da Silva, General Manager of Formifarma Portugal, stresses the importance of market access, demonstrating added value for companies today, as well as the need for a revamp of Portugal’s outdated reimbursement system.   What was your inspiration for creating Formifarma? Having spent my career in various fields of…